| Title | Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety |
| Authors | Huang, Xiaojun Jiang, Qian Hu, Jianda Li, Jianyong Jin, Jie Meng, Fanyi Shen, Zhixiang Liu, Ting Wu, Depei Wang, Jianmin Wang, Jianxiang |
| Affiliation | Peking Univ, Peoples Hosp, Beijing 100044, Peoples R China Fujian Med Univ, Union Hosp, Fuzhou 350004, Fujian, Peoples R China Nanjing Med Univ, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou 310058, Zhejiang, Peoples R China Guangzhou Nanfang Hosp, Guangzhou 510515, Guangdong, Peoples R China Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai 200025, Peoples R China Sichuan Univ, West China Hosp, Chengdu 610041, Peoples R China Soochow Univ, Affiliated Hosp 1, Suzhou 215006, Peoples R China Changhai Hosp Shanghai, Shanghai 200433, Peoples R China Chinese Acad Med Sci, Inst Hematol & Blood Dis Hosp, Tianjin 300020, Peoples R China Peking Union Med Coll, Tianjin 300020, Peoples R China |
| Keywords | chronic myeloid leukemia (CML) dasatinib tyrosine kinase inhibitor long-term follow-up |
| Issue Date | 2019 |
| Publisher | FRONTIERS OF MEDICINE |
| Abstract | Dasatinib is a highly effective second-generation tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML). In 2007, a pivotal phase-2 study of dasatinib as second-line treatment was initiated in 140 Chinese CML patients. This report from the 4-year follow-up revealed that 73% of 59 patients in chronic phase (CML-CP) and 32% of 25 patients in accelerated phase (CML-AP) remained under treatment. The initial dosage of dasatinib for CML-CP and CML-AP patients were 100 mg once daily and 70 mg twice daily (total = 140 mg/ day), respectively. The cumulative major cytogenetic response (MCyR) rate among patients with CML-CP was 66.1% (versus 50.8% at 18 months), and the median time to MCyR was 12.7 weeks. All CML-CP patients who achieved MCyR after a 4-year follow-up also achieved a complete cytogenetic response. The cumulative complete hematological response (CHR) rate among patients with CML-AP was 64% (16/25), with three CML-AP patients achieving CHR between 18 months and 4 years of follow-up; the median time to CHR was 16.4 weeks. The adverse event (AE) profile of dasatinib at 4 years was similar to that at 6 and 18 months. The most frequently reported AEs (any grade) included pleural effusion, headache, and myelosuppression. These long-term follow-up data continue to support dasatinib as a second-line treatment for Chinese patients with CML. |
| URI | http://hdl.handle.net/20.500.11897/547820 |
| ISSN | 2095-0217 |
| DOI | 10.1007/s11684-018-0639-7 |
| Indexed | SCI(E) |
| Appears in Collections: | 人民医院 |
